RELMADA THERAPEUTICS, INC. Increase (Decrease) in Accounts Receivable
RELMADA THERAPEUTICS, INC. (RLMD) reported Increase (Decrease) in Accounts Receivable of $512.43 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-23.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2023-03-23
- RELMADA THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2022 was $512.43K.
| Period end | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|
| 2022-12-31 | $512.43K 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |